Dextromethorphan Market Size & Share, by Dosage Type (Tablets, Syrup); Product Type {Over-the-counter (OTC), Prescription Drug}; Age Group (Pediatric, Adult); Application (Cough, Acute, Chronic Bronchitis, Bronchial Asthma, Sore Throat, Tuberculosis); End-user (Hospitals, Retail Pharmacies, Online Pharmacies, Convenient Stores) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4078
  • Published Date: Mar 03, 2023
  • Report Format: PDF, PPT

Companies Dominating the Dextromethorphan Landscape

    • AstraZeneca PLC      
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • FibroGen, Inc.
    • Novartis AG
    • Abbott Laboratories
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Sunovion Pharmaceuticals Inc.
    • Aurobindo Pharma Limited
    • Zydus Pharmaceuticals Inc.

Browse Key Market Insights with Data Illustration:


In The News

  •  Astellas Pharma Inc. and Iota Biosciences, Inc. announced a merger agreement, following which, Astellas will acquire Iota’s unique bioelectronics technology.

  • AstraZeneca and BenevolentAI entered into a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4078
  • Published Date: Mar 03, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of severe cough and other diseases is estimated to boost the market growth.

The market is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.

Lack of awareness regarding the advantages of dextromethorphan coupled with the high cost associated with the drug and constant fluctuation in the regulations and approvals are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are AstraZeneca PLC, FibroGen, Inc., F. Hoffmann-La Roche Ltd. Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, Merck & Co., Inc., Sunovion Pharmaceuticals Inc., Aurobindo Pharma Limited, Zydus Pharmaceuticals Inc., and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by dosage type, product type, application, age group, end-user, and by region.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying